US FDA News: FDA Approves New Treatment Option for Patients with ALS

The FDA approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.
Read more: FDA Approves New Treatment Option for Patients with ALS